title: Predictive value of baseline plasma D-dimers for chemotherapy- induced thrombocytopenia in patients with stage III colon cancer: a pilot study.
abstract: BACKGROUND
  Chemotherapy-induced thrombocytopenia (CIT) is an important cause of morbitity in patients with cancer.
  
  
  OBJECTIVE
  To investigate the effect of the baseline plasma D-dimer level, an important marker for thrombotic activity, on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer.
  
  
  METHODS
  A total of 43 (28 men) eligible patients were divided into two groups according to whether they exhibited chemotherapy-induced thrombocytopenia: Group 1 (n=21) and Group 2 (n=22). Comparison was made using demographic, histopathologic, and laboratory variables. Additionally, baseline plasma D-dimer levels underwent receiver operation characteristics curve analysis, and areas under the curve were calculated. Sensitivity, specificity, and positive and negative likelihood rates were then determined.
  
  
  RESULTS
  The incidence of chemotherapy-induced thrombocytopenia had a significant correlation with baseline platelet count (r=0.568, P=0.031) and baseline plasma D-dimer levels (r=0.617, P=0.036). When the cut-off point for the latter was set as 498 ng/mL, the area under the curve was 0.89 (95%CI: 0.74-0.93), the sensitivity was 91.4%, the specificity was 89.7%, the positive likelihood rate was 3.64 and the negative likelihood rate was 0.24 for chemotherapy-induced thrombocytopenia diagnosis.
  
  
  CONCLUSIONS
  The baseline level of plasma D-dimer could help to differentiate high- risk patients for chemotherapy-induced thrombocytopenia.
authors.affiliation: Department of Medical Oncology, Mugla Sitki Kocman University Education and Research Hospital, Mugla, Turkey. ozgurtanriverdi@hotmail.com
authors.forename: Ozgur
authors.initials: O
authors.lastname: Tanriverdi
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000740:Anemia / Q000097:blood / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000009:adverse effects; D010865:Pilot Projects; D010976:Platelet Count; D011237:Predictive Value of Tests; D012372:ROC Curve; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013921:Thrombocytopenia / Q000097:blood* / Q000139:chemically induced*
chemical_list: D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D009944:Organoplatinum Compounds; C036309:fibrin fragment D; D002955:Leucovorin; D005472:Fluorouracil